GlaxoSmithKline Issues Update On Rotarix
Retrospective testing of Rotarix, using new molecular detection techniques, has confirmed that material from PCV-1 has been present since the initial stages of the vaccine’s development in the
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.